Clinical trials: completed, in Gabon
COVID-19
Variants of SARS-CoV-2 Causing COVID-19 in Africa
The main objective of this research is to identify and characterize the different molecular variants of SARS-CoV-2, emerging and / or circulating in several countries of Sub-Saharan Africa (Burkina Faso, Côte d'Ivoire, Gabon…
- Trial name
- South-Spike (NCT05311891)
- Testing
- RT PCR
- Where
- 6 sites in Burkina Faso, Chad and 4 more
- Volunteers
- 12,600 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases
Malaria (Plasmodium Falciparum)
Controlled Human Malaria Infection by Mosquito Bites Using a Local Strain of Plasmodium Falciparum
The project aims to reproduce the malaria infection cycle using African mosquitoes, namely Anopheles gambiae and a local strain of Plasmodium parasites.
- Trial name
- BB-LaCHMI-01 (NCT07816497)
- Testing
- Controlled Human Malaria Infection
- Where
- Gabon
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Centre de Recherche Médicale de Lambaréné
Uncomplicated Plasmodium Falciparum Malaria
Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort B1)
This is Cohort B1 of the Platform study (NCT05750628) to evaluate the efficacy and safety of INE963 + Cipargamin in participants with uncomplicated Plasmodium falciparum malaria.
- Trial name
- PLATINUM (NCT07811882)
- Testing
- KAE609 (Cipargamin), SoC (Coartem), INE963
- Where
- 13 sites in Burkina Faso, Côte d’Ivoire and 5 more
- Volunteers
- 95 people
- Sponsor
- Novartis Pharmaceuticals
Uncomplicated Plasmodium Falciparum Malaria
Efficacy, Safety and Tolerability of KAF156 in Combination With Lumefantrine Solid Dispersion Formulation (LUM-SDF) in Pediatric Population With Uncomplicated Plasmodium Falciparum Malaria
This study aimed to determine the efficacy, safety and tolerability of the investigational drug KAF156 in combination with a solid dispersion formulation of lumefantrine (LUM-SDF) in pediatric patients (6 months to < 18 years of…
- Trial name
- KALUMI (NCT04546633)
- Testing
- KAF156, LUM-SDF, Coartem
- Where
- 9 sites in Burkina Faso, Côte d’Ivoire and 3 more
- Volunteers
- 295 people
- Sponsor
- Novartis Pharmaceuticals
Uncomplicated Plasmodium Falciparum Malaria
Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort B2)
This was Cohort B2 of the Platform study (NCT05750628) to evaluate the efficacy and safety of Cipargamin + KLU156 in participants with uncomplicated Plasmodium falciparum malaria.
- Trial name
- PLATINUM (NCT07235033)
- Testing
- KAE609, SoC (Coartem), KLU156
- Where
- 3 sites in Côte d’Ivoire, Gabon and 1 more
- Volunteers
- 60 people
- Sponsor
- Novartis Pharmaceuticals
Multi-drug Resistant Tuberculosis
Treatment of Tuberculosis Multidrug Resistance Treatment of Tuberculosis Multidrug Resistance
The principal objective is to evaluate a cure rate and number of adverse events of with confirmed multidrug-resistant tuberculosis patient treated with a 9months regimen.
- Trial name
- TB-MR (NCT03057756)
- Testing
- Km+ Mfx+ Pto + H + Cfz +E+Z
- Where
- Gabon
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Centre de Recherche Médicale de Lambaréné
Uncomplicated Plasmodium Falciparum Malaria
Efficacy, Safety and Tolerability of KLU156 in Adults and Children With Uncomplicated P. Falciparum Malaria
This study aims to confirm the efficacy, safety and tolerability of KLU156, a fixed dose combination of ganaplacide (KAF156) and a solid dispersion formulation of lumefantrine (lumefantrine-SDF), when administered once daily for…
- Trial name
- KALUMA (NCT05842954)
- Testing
- KLU156, Coartem
- Where
- 33 sites in Burkina Faso, Côte d’Ivoire and 10 more
- Volunteers
- 1,720 people
- Sponsor
- Novartis Pharmaceuticals
Uncomplicated Plasmodium Falciparum Malaria
Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria
This is Cohort A1 of the Platform study (NCT05750628) to evaluate the efficacy and safety of INE963 in participants with uncomplicated Plasmodium falciparum malaria.
- Trial name
- PLATINUM (NCT07235020)
- Testing
- INE963
- Where
- 6 sites in Burkina Faso, Côte d’Ivoire and 4 more
- Volunteers
- 52 people
- Sponsor
- Novartis Pharmaceuticals
Acute Malaria
Phase IIa Proof of Concept Study of M5717-Pyronaridine in Adults and Adolescents With Acute Uncomplicated Plasmodium Falciparum Malaria (CAPTURE 1)
The purpose of this study was to evaluate the safety, efficacy, and pharmacokinetic of the combination M5717 plus pyronaridine in participants with acute uncomplicated Plasmodium falciparum malaria.
- Trial name
- NCT05689047
- Testing
- M5717 330 mg, M5717 500 mg, M5717 660 mg
- Where
- 5 sites in Burkina Faso, Gabon and 2 more
- Volunteers
- 38 people
- Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Malaria
Pan-Malaria Transmission-Blocking Vaccine AnAPN1
Malaria is still responsible for more than 627,000 deaths each year, predominantly among children under 5 years old. Current reductions in deaths have stagnated, and additional setbacks for malaria control programs due to the…
- Trial name
- PamTBVac (NCT05905432)
- Testing
- Vaccine AnAPN1
- Where
- Gabon
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Centre de Recherche Médicale de Lambaréné
SARS CoV 2 Infection, Vaccination; Infection
Monitoring COVID-19 Vaccination Response in Fragile Populations
The present study is part of ORCHESTRA project, a three-year international research project aimed at tackling the coronavirus pandemic.
- Conditions
- SARS CoV 2 Infection, Vaccination; Infection, Breakthrough Infection
- Trial name
- ORCHESTRA-4 (NCT05222139)
- Testing
- COVID-19 vaccination
- Where
- 20 sites in Argentina, Gabon and 5 more
- Volunteers
- 8,894 people
- Sponsor
- University of Bologna
Mycobacterium Tuberculosis Infection
Evaluation of Efficacy and Safety of VPM1002 in Comparison to BCG in Prevention of Tb Infection in Infants
The trial is designed as a phase III, double-blind, multicenter, randomized, single administration, active-controlled, parallel-group design with two groups of newborn infants receiving either VPM1002 or BCG SII (1:1 allocation)…
- Trial name
- VPM1002 (NCT04351685)
- Testing
- VPM1002, BCG SII
- Where
- 12 sites in Gabon, Kenya and 3 more
- Volunteers
- 6,940 people, healthy volunteers welcome
- Sponsor
- Serum Institute of India Pvt. Ltd.
Hookworm Disease, Hookworm Infection
Study of Co-administered Na-APR-1 (M74) and Na-GST-1 in Gabonese Children
Double blind, randomized, controlled, dose-escalation Phase 1 clinical trial in hookworm-exposed children aged 6 to 10 years living in the area of Lambaréné, Gabon.
- Trial name
- NCT02839161
- Testing
- Na-GST-1/Alhydrogel, Na-APR-1 (M74)/Alhydrogel, Hepatitis B Vaccine
- Where
- Gabon
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Baylor College of Medicine
Malaria, HIV/AIDS
Improving Maternal heAlth by Reducing Malaria in African HIV Women
Trial to evaluate the safety and efficacy of DHA-PPQ for Intermittent Preventive Treatment (IPTp) in HIV-infected pregnant women receiving cotrimoxazole prophylaxis (CTXp) and antiretroviral (ARV) drugs and using long lasting…
- Conditions
- Malaria, HIV/AIDS, Pregnancy Related
- Trial name
- MAMAH (NCT03671109)
- Testing
- Dihydroartemisinin-piperaquine (DHA-PPQ)
- Where
- 2 sites in Gabon, Mozambique
- Volunteers
- 666 people, healthy volunteers welcome
- Sponsor
- Barcelona Institute for Global Health
SARS-CoV2 Infection, COVID-19
Prevalence and Impact of COVID-19 on Maternal and Infant Health in African Populations
There is growing evidence that COVID-19 threatens maternal and perinatal health. Pregnant women are at higher risk of severe complications (severe pneumonia, hospitalizations, intensive care unit admission, invasive mechanical…
- Trial name
- MA-CoV (NCT05303168)
- Where
- 2 sites in Gabon, Mozambique
- Volunteers
- 1,000 people
- Sponsor
- Barcelona Institute for Global Health
Vitamin D Deficiency, Immunosuppression
Helminth Infection During Pregnancy on Vitamin D Regulation: HELMVIT Study
Purpose: To examine whether helminth infection during pregnancy alters Vitamin-D-metabolism and reactivity of the child's immune system Hypothesis: Helminth infection during pregnancy is associated with altered Vitamin D levels…
- Trial name
- HELMVIT (NCT04324853)
- Testing
- Microscopy ( Urine filtration), UCAA test, qPCR,, Microscopy (Kato Katz, Coproculture, Harada Mori, MIF), qPCR,
- Where
- Gabon
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Centre de Recherche Médicale de Lambaréné
Tuberculosis
Evaluation of the VOT Among Tuberculosis Patients From Lambaréné
This pilot study aimed to assess the feasibility of using an instant messenger to monitor drug intake in tuberculosis patients and to assess cash incentive to improve adherence to drug intake
- Trial name
- dotsapp (NCT05865626)
- Testing
- VOT with and without cash incentive
- Where
- Gabon
- Volunteers
- 30 people
- Sponsor
- Centre de Recherche Médicale de Lambaréné
Ebola Virus Disease
Safety and Immunogenicity of the rVSVΔG-ZEBOV-GP Ebola Virus Vaccine Candidate in Children Living in Lambaréné, Gabon
LA rVSVΔG-ZEBOV-GP -02-PED is a Phase 1/2, randomized, controlled open label trial. The LA rVSVΔG-ZEBOV-GP -02-PED trial aims primarily to assess the clinical significance of shedding of the rVSV RNA following vaccination with…
- Trial name
- EBOLAPED (NCT05130398)
- Testing
- rVSVΔG-ZEBOV-GP, V920, Fibre and equilibrate breakfast and lunch, Active detection and treatment of pathogens
- Where
- Gabon
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Centre de Recherche Médicale de Lambaréné
Coronavirus Infection, Africa
Important Data on COVID-19 Profile in Africa
The purpose of this study is to Understand the natural history of Coronavirus 2019 (COVID-19) infection to better define the period of infectiousness and transmissibility and to establish biobanks of COVID-19 blood and mucosal…
- Trial name
- AIDCO (NCT04847817)
- Where
- 2 sites in Gabon
- Volunteers
- 574 people
- Sponsor
- Centre de Recherche Médicale de Lambaréné
Uncomplicated Plasmodium Falciparum Malaria
Pyronaridine and Artesunate (3:1) in Children With Acute Uncomplicated Plasmodium Falciparum Malaria
The purpose of this study is to evaluate three dose levels of a combination tablet and a fixed dose granule formulation of pyronaridine and artesunate (PA) for the treatment of acute uncomplicated falciparum malaria in children.
- Trial name
- NCT00331136
- Testing
- Pyronaridine-Artesunate
- Where
- Gabon
- Volunteers
- 60 people
- Sponsor
- Medicines for Malaria Venture